Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Meglumine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Open clinical studies with Gd-DTPA (dimeglumine gadopentetate) in cerebral and spinal diseases - Summary of studies at 22 hospitals.
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_A23BSA_study_synopsis.pdf
    View full study record
    Document reference: 28835
    Study title: Open label study of Gadopentetate Dimeglumine as a magnetic resonance imaging (MRI) contrast agent in pediatric patients presenting with symptoms of central nervous system (CNS) lesions.
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_88492_study_synopsis.pdf
    View full study record
    Document reference: 28831
    Study title: Open label study of Gadopentetate Dimeglumine as an MRI contrast agent in pediatric patients presenting with symptoms of central nervous system lesions.
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_88490_study_synopsis.pdf
    View full study record
    Document reference: 28828
    Study title: Open-Label Study of Gadopentetate Dimeglumine as an magnetic resonance imaging (MRI) contrast agent in pediatric patients presenting with symptoms of central nervous system lesions.
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_88493_study_synopsis.pdf
    View full study record
    Document reference: 28832
    Study title: Open-Label Study of Gadopentetate Dimeglumine as an MRI Contrast Agent in Pediatric Patients Presenting with Symptoms of Central Nervous System Lesions
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_88488_study_synopsis.pdf
    View full study record
    Document reference: 28826
    Study title: Open-Label study of Gadopentetate Dimeglumine as an MRI Contrast Agent in Pediatric Patients Presenting with Symptoms of Central Nervous System Lesions.
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_88489_study_synopsis.pdf
    View full study record
    Document reference: 28827
    Study title: Open-Label Study of Gadopentetate Dimeglumine as an MRI Contrast Agent in Pediatric patients Presenting with Symptoms of Central Nervous System Lesions.
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_88491_study_synopsis.pdf
    View full study record
    Document reference: 28830
    Study title: Uncontrolled multicentre study for the further demonstration of the tolerance and efficacy of dimeglumine gadopentatate on intravenous use in magnetic resonance imaging in adults
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_86110_study_synopsis.pdf
    View full study record
    Document reference: 28816
    Study title: Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA); Herborn CU; Invest. Radiol.; 2007 vol.42 p.58-62Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA); Herborn CU; Invest. Radiol.; 2007 vol.42 p.58-62
    Active substance: GADOTERIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28872
    Study title: Intersticial MR lymphography with gadoterate meglumine: initial experience in humans;Ruehm SG; Radiology; 2001 vol.220 p.816-821Intersticial MR lymphography with gadoterate meglumine: initial experience in humans;Ruehm SG; Radiology; 2001 vol.220 p.816-821
    Active substance: GADOTERIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28860
    Study title: Comparison of Safety and Efficacy of Gadobenate Dimeglumine and Gadopentetate Dimeglumine in Magnetic Resonance Imaging of Central Nervous System Disorders in Pediatric Patients.
    Active substance: FUSIDIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28721
    Study title: Comparison of Safety and Efficacy of Gadobenate Dimeglumine and Gadopentetate Dimeglumine in Magnetic Resonance Imaging of Central Nervous System Disorders in Pediatric Patients.
    Active substance: GADOBENIC ACID
    Study summary document link (including results): EUdraCT-datafields for publication-Bracco-MultiHance_B19036036.xls
    View full study record
    Document reference: 28800
    Study title: Open clinical studies with Gd-DTPA (dimeglumine gadopentetate) in cerebral and spinal diseases - summary of studies at 22 hoospitalsJ Mol Neurosci. 1996 Summer;7(2):87-90.Early diagnosis of Nelson's syndrome. Kasperlik-Zaluska AA, Walecki J, Jeske W, Migdalska B, Janik J, Bonicki W, Brzeziński J, Makowska A, Brzezińska A.
    Active substance: GADODIAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 28812
    Study title: Invest Radiol. 1991 Jul;26(7):665-70 A comparison of iohexol and diatrizoate-meglumine in children undergoing cardiac catheterization. Pelech AN, Allard SM, Hurd RT, Giddins NG, Collins GF Invest Radiol. 1991 Jul;26(7):665-70 A comparison of iohexol and diatrizoate-meglumine in children undergoing cardiac catheterization. Pelech AN, Allard SM, Hurd RT, Giddins NG, Collins GF
    Active substance: IOHEXOL
    Study summary document link (including results):
    View full study record
    Document reference: 30376
    Study title: A comparison of iohexol and diatrizoate-meglumine in children undergoing cardiac catheterization. Investigative radiology (1991), 26(7), 665-70 Pelech AN 1991
    Active substance: IOHEXOL
    Study summary document link (including results): 2011-09 GE Omnipaque response List of published articles.doc
    View full study record
    Document reference: 48863
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 06:59:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA